Rationally designed viruses for use as vaccines or solid tumor therapies

Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies. Both programs rely on scalable, low-cost manufacturing.

Safe and effective live-attenuated vaccines, presenting all target antigens

Target customized oncolytics to treat primary tumors and shrink off-site metastases


RSV hospitalizations among adults 65+ no vaccine

48.8 million

Flu cases in 2017-18, current vaccines <37% effective

1 in 8

US women (about 12%) will develop invasive breast cancer during lifetime.

Our breakthrough approach to live-attenuated virus design

1. Recode

2. Synthesize

3. Transfect

4. Recover

  • February 13, 2020

    Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19

    FARMINGDALE, N.Y., Feb. 13, 2020 /PRNewswire/ — Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced a collaboration with the Serum Institute of India to rapidly co-develop a live-attenuated vaccine against the emergent coronavirus. There are no licensed vaccines or therapeutics for this novel coronavirus, now referred to as COVID-19. A live-attenuated vaccine […]

    Full Story
  • January 15, 2020

    Gates vets at Adjuvant back Codagenix’s software-driven approach to recoding RSV, flu, oncolytic viruses and more

    Software is eating the way we make vaccines, and it has earned Farmingdale, NY-based biotech $20 million for a platform tech theoretically applicable to any virus — from influenza to oncolytic viruses targeted at cancer. Adjuvant Capital, the group of Gates Foundation veterans out to test a VC model for global health, led the Series […]

    Full Story